Anti-idiotypic antibodies which induce an immune response against epidermal growth factor receptor
AssigneeMerck Patent GmbH
InventorsAna Carceller, Elisabet Rosell, Alicia Gomez, Jaume Adan, Jaume Piulats
Life of this patent
Estimating the term…
Abstract
The present invention relates to anti-idiotypic antibodies which induce an immune response against tumors, bearing as antigen the epidermal growth factor receptor (EGFR). The antibodies of the invention may mimic said antigen. As preferred embodiment the antibodies of the invention derive from mAB 425 (ATCC HB 9629) or a humanized or chimeric derivative thereof.
Claims8
An isolated monoclonal true internal image anti-idiotypic antibody (Ab2) containing antigen recognition sites which mimic antigenic regions of epidermal growth factor receptor (EGFR) and thereby induce an immune response against EGFR when administered to a host, obtained from a murine hybridoma produced by fusing mouse splenocytes immunized with idiotypic (Ab1) murine Mab 425 (ATCC HB 9629) with myeloma cells, wherein the CDR regions and the FR regions of said anti-idiotypic antibody comprise an amino acid sequence selected from SEQ ID NO:2, 4, 6, 8, 10or 12, or a humanized or chimeric antibody thereof.
An isolated monoclonal true internal image anti-idiotypic antibody (Ab2) containing antigen recognition sites which mimic antigenic regions of epidermal growth factor receptor (EGFR) and thereby induce an immune response against EGFR when administered to a host, obtained from a murine hybridoma produced by fusing mouse splenocytes immunized with idiotypic (Ab1) murine Mab 425 (ATCC HB 9629), with myeloma cells, comprising an amino acid sequence coding for the CDR and FR regions of said anti-idiotypic antibody encoded by a nucleotide sequence selected from SEQ ID NO:
- 1, 3, 5, 7, 9 or 11, or humanized or chimeric antibody thereof.
Dependencies are inferred from the claim text.